MEI Pharma Inc (MEIP):企業のM&A・提携動向(医療分野)

◆英語タイトル:MEI Pharma Inc (MEIP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:GDPH61270D
◆発行会社(調査会社):GlobalData
◆発行日:2017年2月17日
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD500 ⇒換算¥56,000見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD750 ⇒換算¥84,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
MEI Pharma, Inc. (MEI), formerly Marshall Edwards Inc., is an oncology company that focuses on the development of drugs for the treatment of cancer. The company’s drug candidates include pracinostat, an oral HDAC inhibitor which is intended for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome and myelofibrosis. Its clinical development pipeline also includes ME-344, a mitochondrial inhibitor for the treatment of HER2-negative Breast indication; and ME-401, an oral PI3K delta inhibitor for B-cell malignancies. The company has partnership with Helsinn Healthcare, SA, to develop Pracinostat in AML and myelodysplastic syndrome indications. MEI is headquartered in San Diego, California, the US.

MEI Pharma Inc (MEIP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
MEI Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
MEI Pharma Acquires PWT143 From Pathway Therapeutics 11
MEI Pharma Completes Acquisition Of Rights To Pracinostat From S*BIO For Up To US$76 Million 11
Marshall Edwards Completes Acquisition Of Intellectual Property Portfolio From Novogen 13
Partnerships 14
Helsinn Enters into Agreement with MEI Pharma 14
Licensing Agreements 15
Helsinn Enters into Licensing Agreement with MEI Pharma 15
MEI Pharma Enters into Licensing Agreement with Ligand Pharma 16
MEI Pharma Enters into Licensing Agreement with CyDex Pharma 17
Marshall Edwards Enters Into Licensing Agreement With Ausio Pharma 17
Equity Offering 18
MEI Pharma Raises USD46 Million in Public Offering of Shares 18
MEI Pharma Completes Public Offering Of Shares For US$35 Million 20
MEI Pharma Completes Public Offering Of Shares For US$15 Million 21
MEI Pharma Completes Private Placement Of Units For US$27.5 Million 22
Marshall Edwards Completes Rights Offering Of Units For US$5.2 Million 24
Marshall Edwards Completes Private Placement Of Common Stock For US$2 Million 25
Marshall Edwards Completes Private Placement Of Common Stock For US$2 Million 26
Marshall Edwards Completes Private Placement Of Common Stock For US$1.1 Million 28
Marshall Edwards Completes First Tranche Of Public Offering Of Common Stock For US$0.13 Million 29
MEI Pharma Inc – Key Competitors 31
Key Employees 32
Locations And Subsidiaries 33
Head Office 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
MEI Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
MEI Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
MEI Pharma Inc, Deals By Therapy Area, 2011 to YTD 2017 8
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
MEI Pharma Acquires PWT143 From Pathway Therapeutics 11
MEI Pharma Completes Acquisition Of Rights To Pracinostat From S*BIO For Up To US$76 Million 11
Marshall Edwards Completes Acquisition Of Intellectual Property Portfolio From Novogen 13
Helsinn Enters into Agreement with MEI Pharma 14
Helsinn Enters into Licensing Agreement with MEI Pharma 15
MEI Pharma Enters into Licensing Agreement with Ligand Pharma 16
MEI Pharma Enters into Licensing Agreement with CyDex Pharma 17
Marshall Edwards Enters Into Licensing Agreement With Ausio Pharma 17
MEI Pharma Raises USD46 Million in Public Offering of Shares 18
MEI Pharma Completes Public Offering Of Shares For US$35 Million 20
MEI Pharma Completes Public Offering Of Shares For US$15 Million 21
MEI Pharma Completes Private Placement Of Units For US$27.5 Million 22
Marshall Edwards Completes Rights Offering Of Units For US$5.2 Million 24
Marshall Edwards Completes Private Placement Of Common Stock For US$2 Million 25
Marshall Edwards Completes Private Placement Of Common Stock For US$2 Million 26
Marshall Edwards Completes Private Placement Of Common Stock For US$1.1 Million 28
Marshall Edwards Completes First Tranche Of Public Offering Of Common Stock For US$0.13 Million 29
MEI Pharma Inc, Key Competitors 31
MEI Pharma Inc, Key Employees 32

List of Figures
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

★調査レポート[MEI Pharma Inc (MEIP):企業のM&A・提携動向(医療分野)] (コード:GDPH61270D)販売に関する免責事項を必ずご確認ください。
★調査レポート[MEI Pharma Inc (MEIP):企業のM&A・提携動向(医療分野)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆